President Trump Just Reclassified Marijuana. Are Green Thumb, Tilray, and Trulieve Stocks No-Brainer Buys?

On Dec. 18, 2025 an executive order directed the Attorney General to reschedule marijuana from Schedule I to Schedule III, formally recognizing medical use and potentially exempting cannabis firms from IRS Code Section 280E (which currently prevents deductions for items such as payroll and rent). The regulatory shift could materially boost profitability, expand access to banking and attract investment (Tilray announced U.S. medical expansion), but near-term fundamentals remain mixed: Tilray reported a Q3 2025 net loss of $793.5 million, Trulieve posted a Q3 net loss of $27 million, and Green Thumb trades at a forward P/E of 34.6, so valuation and profitability risks persist despite the favorable policy development.

Analysis

Market structure: Schedule I→III materially benefits vertically integrated MSOs (Green Thumb/GTBIF, Trulieve/TCNNF) and multi-national growers with U.S. plans (Tilray/TLRY) via restored deductibility (280E) and easier banking. Expect margin expansion of 400–800bps for operators that immediately reclassify tax treatment and consolidate leases; smaller mom‑and‑pop cultivators face pressure as capital flows to scale. Financial intermediaries (regional banks, debt markets) will tighten spreads for compliant MSOs; equity volatility should compress 20–40% as regulatory tail risk declines.

Risk assessment: Key tail risks include judicial challenges, a stalled DEA/AG implementation (90–180 days), or IRS limiting retroactivity of 280E relief, any of which could wipe 20–50% off re‑rated equity gains. Short-term (days-weeks) price spikes reflect headline flows; medium term (3–12 months) depends on IRS/FinCEN guidance and bank onboarding; long term (12–36 months) the industry faces pharma competition if cannabinoids route through FDA pathways, compressing retail margins.

Trade implications: Favor selective long exposure to TLRY (US expansion optionality) and GTBIF for scale — size positions to 1.5–3% portfolio each — while avoiding unprofitable regional names without balance‑sheet liquidity. Use 9–12 month TLRY call spreads (buy 25–35% OTM, sell 60% width) and covered calls on GTBIF to monetize anticipated IV decline; consider short small-cap cannabis ETFs or names that rallied >60% post‑announcement.

Contrarian view: Market likely underestimates implementation friction and overestimates near-term cashflow benefits; valuations that price full 280E relief now are vulnerable if IRS retroactivity is denied. Historical parallels: alcohol/light‑beer deregulation created winners but also rapid consolidation and margin normalization — expect M&A arbitrage opportunities rather than sustained alpha for all incumbents.

Key Decisions for Investors

• Establish a 2–3% long position in TLRY within 2–4 weeks (risk/reward favors upside from U.S. rollout); hedge with a 9–12 month 25–35% OTM bull call spread sized to limit max loss to ~50% of notional.
• Initiate a 1–2% long in GTBIF but sell 3-month covered calls at a strike ~10–15% above current price to collect premium while IV decompresses; reduce position by 50% if shares rally >40% in 30 days (take profits on momentum).
• Short or underweight unprofitable smaller MSOs or cannabis small‑cap ETFs that gained >60% since Dec 18; size shorts to 0.5–1% portfolio and cover if spreads tighten or company announces positive IRS/FinCEN guidance.
• Catalyst rules: monitor DOJ/DEA formal reclassification timeline and IRS 280E guidance closely — if no definitive IRS guidance within 90 days, reduce cannabis equity exposure by 25–50%; if banks (≥3 regional banks) publicize onboarding within 120 days, add 50% to TLRY/GTBIF positions.